Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine

CYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any severity and serotype, serotype specific efficacy, efficacy dependent on baselin...

Full description

Saved in:
Bibliographic Details
Main Authors: Wilder-Smith, Annelies, Massad, Eduardo
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2016
Subjects:
Dengue
Vaccine
Efficacy
Age indication
Online Access:https://hdl.handle.net/10356/80254
http://hdl.handle.net/10220/40437
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
id sg-ntu-dr.10356-80254
record_format dspace
spelling sg-ntu-dr.10356-802542020-11-01T05:29:32Z Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine Wilder-Smith, Annelies Massad, Eduardo Lee Kong Chian School of Medicine (LKCMedicine) Dengue Vaccine Efficacy Age indication CYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any severity and serotype, serotype specific efficacy, efficacy dependent on baseline seropositivity, efficacy against hospitalizations and efficacy against severe disease. Because of the higher efficacy and the absence of a safety signal, the age group with the best benefit of the use of CYD-TDV is individuals aged 9 and above - the age group for which licensure is now being sought. Accepted version 2016-04-15T06:13:47Z 2019-12-06T13:45:56Z 2016-04-15T06:13:47Z 2019-12-06T13:45:56Z 2016 Journal Article Wilder-Smith, A., & Massad, E. (2016). Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Review of Vaccines, 15(4), 437-441. 1476-0584 https://hdl.handle.net/10356/80254 http://hdl.handle.net/10220/40437 10.1586/14760584.2016.1143366 en Expert Review of Vaccines © 2016 Taylor & Francis. This is the author created version of a work that has been peer reviewed and accepted for publication by Expert Review of Vaccines, Taylor & Francis. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1586/14760584.2016.1143366]. 11 p. application/pdf
institution Nanyang Technological University
building NTU Library
continent Asia
country Singapore
Singapore
content_provider NTU Library
collection DR-NTU
language English
topic Dengue
Vaccine
Efficacy
Age indication
spellingShingle Dengue
Vaccine
Efficacy
Age indication
Wilder-Smith, Annelies
Massad, Eduardo
Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
description CYD-TDV is the first dengue vaccine to have completed Phase 3 efficacy trials. Efficacy was consistently higher in those aged 9 and above for all variables studied: efficacy against virologically confirmed dengue of any severity and serotype, serotype specific efficacy, efficacy dependent on baseline seropositivity, efficacy against hospitalizations and efficacy against severe disease. Because of the higher efficacy and the absence of a safety signal, the age group with the best benefit of the use of CYD-TDV is individuals aged 9 and above - the age group for which licensure is now being sought.
author2 Lee Kong Chian School of Medicine (LKCMedicine)
author_facet Lee Kong Chian School of Medicine (LKCMedicine)
Wilder-Smith, Annelies
Massad, Eduardo
format Article
author Wilder-Smith, Annelies
Massad, Eduardo
author_sort Wilder-Smith, Annelies
title Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
title_short Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
title_full Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
title_fullStr Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
title_full_unstemmed Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
title_sort age specific differences in efficacy and safety for the cyd-tetravalent dengue vaccine
publishDate 2016
url https://hdl.handle.net/10356/80254
http://hdl.handle.net/10220/40437
_version_ 1683494355287932928

Similar Items